Carrie Yeung1, Teresa M Petrella2, Frances C Wright3, Wadid Abadir4, Nicole J Look Hong3. 1. a Division of Medical Oncology , University of Toronto , Toronto , ON , Canada. 2. b Division of Medical Oncology , Sunnybrook Health Sciences Centre , Toronto , ON , Canada. 3. c Division of Surgical Oncology, Sunnybrook Health Sciences Centre , University of Toronto , Toronto , ON , Canada. 4. d Division of Dermatology , University of Toronto , Toronto , ON , Canada.
Abstract
BACKGROUND: Diphencycprone (DPCP) is an immune contact sensitizer applied to melanoma lesions. Early studies show favorable efficacy. We present the first North-American series of patients treated with DPCP. METHODS: A single center retrospective study of patients with in-transit or unresectable melanoma lesions treated with DPCP from December 1,2014 to December 31,2015 was completed. Primary objectives were response rate and toxicity. Secondary objective was health-related quality of life assessment with the Functional Assessment of Cancer Therapy-Melanoma (FACT-M) questionnaire. RESULTS: Fifteen consecutive patients were identified with median age of 78 (range 43-92). 73% of patients had prior treatment. Two patients (13%) had a complete response after 25 and 32 weeks, respectively. Four patients (27%) had a partial response with a mean treatment time of 30 weeks (range 6-51 weeks). Six (40%) had stable disease. Six patients stopped DPCP - three from systemic progression and three from toxicity. The most common toxicity was blisters; one patient had significant skin ulceration that resolved on stopping DPCP. Median FACT-M score was 142.95 (possible total 172). Mean overall follow-up time was 22.7 weeks. CONCLUSION: DPCP is a feasible option for in-transit and other melanoma cutaneous lesions ineligible/refractory to surgery and may delay need for systemic therapy.
BACKGROUND:Diphencycprone (DPCP) is an immune contact sensitizer applied to melanoma lesions. Early studies show favorable efficacy. We present the first North-American series of patients treated with DPCP. METHODS: A single center retrospective study of patients with in-transit or unresectable melanoma lesions treated with DPCP from December 1,2014 to December 31,2015 was completed. Primary objectives were response rate and toxicity. Secondary objective was health-related quality of life assessment with the Functional Assessment of Cancer Therapy-Melanoma (FACT-M) questionnaire. RESULTS: Fifteen consecutive patients were identified with median age of 78 (range 43-92). 73% of patients had prior treatment. Two patients (13%) had a complete response after 25 and 32 weeks, respectively. Four patients (27%) had a partial response with a mean treatment time of 30 weeks (range 6-51 weeks). Six (40%) had stable disease. Six patients stopped DPCP - three from systemic progression and three from toxicity. The most common toxicity was blisters; one patient had significant skin ulceration that resolved on stopping DPCP. Median FACT-M score was 142.95 (possible total 172). Mean overall follow-up time was 22.7 weeks. CONCLUSION:DPCP is a feasible option for in-transit and other melanoma cutaneous lesions ineligible/refractory to surgery and may delay need for systemic therapy.
Authors: Claudia Robles-Planells; Sofia A Michelson; Javier Mena; Daniela Escrig; Juan L Rojas; Giselle Sanchez-Guerrero; Ronny Hernández; Carlos Barrera-Avalos; Leonel E Rojo; Daniela Sauma; Alexis M Kalergis; Mónica Imarai; Ricardo Fernández; Carolina A Robles; Elías Leiva-Salcedo; Rocio Santander; Alejandro Escobar; Claudio Acuña-Castillo Journal: Front Pharmacol Date: 2019-10-22 Impact factor: 5.810
Authors: Ivana Lameiras Gibbons; Marina Sonagli; Eduardo Bertolli; Mariana Petaccia de Macedo; Clovis Antonio Lopes Pinto; João Pedreira Duprat Neto Journal: An Bras Dermatol Date: 2018-03 Impact factor: 1.896
Authors: Tavis Read; Scott Webber; Janine Thomas; Michael Wagels; Helmut Schaider; H Peter Soyer; B Mark Smithers Journal: BMJ Open Date: 2017-10-06 Impact factor: 2.692